Programme

An exciting development this year has the investment event being held on-site with the AusBiotech national conference, and will feature a full-day programme of impressive keynote speakers as well as up to 28 company presentations, showcasing the potential of life science companies to an anticipated 400 investors and global pharmaceutical companies.

Presenting companies

Further presenting companies will be added to the programme in coming weeks.

Keynote Speakers

Karimah Es Sabar, Chief Executive Officer & Partner, Quark Ventures Inc., Canada

KarimahEsSabar2_grey-200x300.jpg

A highly-recognised Canadian life sciences leader with broad global experience, Karimah Es Sabar has had a successful career spanning multi-national pharmaceutical, biotechnology companies, start-up, not-for-profit organisations and venture investment firm. Ms Es Sabar will share her knowledge with attendees at the investment meeting on the Canadian biotech market, VC landscape and development of Quark Venture's life sciences fund with China’s GF Securities a leading investment bank, which is among the largest of its kind in the country. The fund is diversified to invest globally in disruptive pre-clinical platforms, clinical stage companies, IPOs and publicly traded companies in therapeutics, vaccines, medical devices, health IT, health AI and novel emerging convergent technologies.

Prior to Quark Ventures, Ms Es Sabar was President and CEO of the Canada's Centre for Drug Research and Development (CDRD), and responsible for developing and executing on the overall strategic direction of the organisation. During her time at CDRD, Ms Es Sabar enabled new public and private sector funding in excess of $180M, multiple commercial transactions including six spin out companies and an M&A, and grew the organisation with expanded national and international reach to include partnerships right across Canada, and in 12 countries on five continents – firmly establishing its reputation as one of the world’s leading pre-clinical translational research and commercialisation centres.

Niels Emmerich, Ph.D, Vice President, Global Head Search & Evaluation, AbbVie

Niels Emmerich.jpg

After joining in 2011 Niels has held several positions at AbbVie, including Global Commercial Leader for a late-stage oncology program, Director and Head of Commercial Business Development for Oncology, Senior Director and Head of Search and Evaluation, Oncology, and most recently Vice President and Global Head of Search and Evaluation. Transactions that Niels was involved in include acquisitions (Pharmacyclics, Stemcentrx), R&D collaborations and license agreements (Argen-X, CALIBR, CytomX, Dong-A-ST, Harpoon, M2Gen, MD Anderson PureMHC, Turnstone, X-Chem) and venture investments. Prior to joining AbbVie Niels was CEO of BioPheresis, co-founder and COO of immatics, and working for McKinsey & Company. Niels attended University of Tuebingen and received a Master’s in Biology and a Ph.D. in Immunology.

Dr Patrik Frei, founder & CEO, Venture Valuation AG, Switzerland

Patrik_Frei.jpg

Dr Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland. He started the company in 1999 when he noticed a need for independent valuation services in high growth industries during a collaboration with Novartis Venture Fund, which became his first client. Since then he has been involved in over 450 valuations for investors as well as biotech, Pharma and medtech companies. Patrik graduated from the Business University of St. Gallen and completed his Ph.D thesis (”Assessment and valuation of high growth companies”) at the Swiss Federal Institute of Technology, EPFL Lausanne. Patrik was a board member and one of the original founders of Ineo, a holding company of the Swiss dental implant VC-backed firm Thommen Medical and also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company, where he successfully out-licensed a portfolio of 4 products. Furthermore, Patrik was member of the board of Aventron AG (AVEN:Berne) a publicly quoted cleantech company, which raised over USD 160m during his time as board member. Patrik’s articles have been published in a number of scientific journals and he has also lectured at Seoul National University, South Korea, EPFL Lausanne, University of St. Gallen and gives regular workshops on valuation.

Giri Tenneti, Senior Manager, Issuer Services, ASX Limited

Giri Tenneti.jpg